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Changes to the lateral geniculate nucleus in Alzheimer’s disease but not dementia with
Lewy bodies
Aims: Complex visual hallucinations occur in 70% of
dementia with Lewy bodies (DLB) cases and significantly
affect patient well-being. Visuo-cortical and retinal abnor-
malities have been recorded in DLB and may play a role in
visual hallucinations. The present study aimed to investi-
gate the lateral geniculate nucleus (LGN), a visual relay
centre between the retina and visual cortex, to see if
changes to this structure underlie visual hallucinations in
DLB. Methods: Fifty-one [17 probable DLB, 19 control and
15 probable Alzheimer’s disease (AD)] cases were recruited
for a functional magnetic resonance imaging study, in
which patients’ response to a flashing checkerboard stimu-
lus was detected and measured in the LGN, before compari-
son across experimental groups. Additionally, post mortem
LGN tissue was acquired for a cross-sectional study using
20 (six DLB, seven control and seven AD) cases and ana-
lysed using stereology. α-Synuclein, phosphorylated tau
and amyloid-β pathology was also assessed in all cases.
Results: DLB cases did not significantly differ from controls
on neuroimaging, morphometry or pathology. However, a
significant increase in amyloid-β pathology, a reduction in
number of parvocellular neurones and magnocellular
gliosis was found in AD cases compared with control and
DLB cases. Conclusions: These findings suggest that the
early visual system is relatively spared in DLB, which
implies that upstream visual structures may be largely
responsible for the generation of hallucinatory percepts.
The significance of the degeneration of the LGN in AD
cases is uncertain.
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Introduction
Dementia with Lewy bodies (DLB) accounts for approxi-
mately 20% of demented cases at autopsy [1] and is the
second most common form of degenerative dementia after
Alzheimer’s disease (AD) [2]. Visual hallucinations occur
in 60–80% of DLB cases [3] and have been shown to have
a profound effect on quality of life for patients [4,5] and
their carers [6]. Typically, the hallucinations are well-
formed and often involve people, disembodied faces,
animals and objects [7].
Although other visual abnormalities frequently occur
in DLB [1], the pathophysiological changes that may give
rise to these phenomena remain poorly understood. Four
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studies using small numbers of DLB patients have shown
retinal abnormalities consisting of α-synuclein deposition
[8] (challenged by Ho et al. [9]) and other cytoplasmic
inclusions [10], retinal nerve fibre thinning [11] and
electroretinogram alterations [12]. Beyond the retina,
however, no evidence has yet been provided for pathologi-
cal alterations in other parts of the afferent visual path-
ways in DLB.
Changes have also been found in the occipital lobe of
DLB cases that have experienced visual hallucinations
[13,14]. Other studies employing transcranial magnetic
stimulation to elicit phosphenes, an experience of seeing
light in the absence of real visual input, have shown a
lower threshold of stimulation in phosphene elicitation
in DLB who hallucinate more frequently and severely,
suggesting occipital hyperexcitation [15].
The lateral geniculate nucleus (LGN) is the first major
visual processing region in the brain, and it plays a vital
role in relaying information from the retinal ganglion
cells, which comprise the optic nerve emanating from
the retina, to the primary visual cortex [16]. Only a
few studies have been conducted into how the LGN is
affected under neurodegenerative conditions. Sparse tau
pathology has been recorded in AD and progressive
supranuclear palsy [17], whereas limited amyloid-β
pathology [18] but no Lewy body pathology has been
found in DLB [19]. In light of the relative paucity of data
on the LGN in DLB, the aim of this study was to investi-
gate whether there are abnormalities in this visual struc-
ture in DLB that may contribute to the generation of
complex visual hallucinations.
To carry out this study, DLB cases were compared with
age-matched control cases and ‘disease control’ AD cases.
The study objectives were:
1 To investigate whether there are changes to the excit-
ability of the LGN, by assessing functional magnetic
resonance imaging (fMRI) in response to a visual stimu-
lus and analysis of local gamma amino-butyric acid
(GABA)ergic interneurons in post mortem tissue.
2 To evaluate whether there are changes to neuronal and
glial cell populations in the LGN across groups using
stereological analysis.
3 To assess whether changes occur to neuronal sub-
populations of the LGN, using densitometric analysis of
populations differentiated by calcium-binding proteins
parvalbumin and calretinin [20].
4 To investigate amyloid-β, tau and Lewy body pathology
to quantify neuropathological lesions within the LGN.
Materials and methods
Neuroimaging protocol
Details of participant selection, neuropsychological and
neuropsychiatric assessment, and fMRI protocol have
been previously reported [14]. The study was approved by
the local ethics committee (Sunderland NREC). The DLB
and AD diagnosis was made independently by two experi-
enced senior clinicians (JO’B and JPT).
Participants were scanned on a 3T whole body MRI
scanner (Achieva scanner; Philips Medical Systems, Best,
The Netherlands). A standard whole brain structural scan
(3D) MPRAGE was acquired, and functional MRI data were
collected with a gradient-echo echo planar imaging
(EPI) sequence [repetition time (TR) = 1.92 s; echo time
(TE) = 40 ms; field of view 192 × 192 mm2; matrix size
64 × 64, flip angle 90°, 27 slices, slice thickness 3 mm,
slice gap 1 mm]. The stimulus consisted of five 19.2 s
blocks of a circular flashing (7.5 Hz) black-and-white
checkerboard, alternating with five 19.2 s baseline blocks
of a blank screen.
Data were processed using SPM5 (Wellcome Trust
Centre for Neuroimaging, University College London,
London, UK) (http://www.fil.ion.ucl.ac.uk/spm/). The
structural scan was segmented into grey and white matter
and spatially normalised using standard segmentation.
The fMRI images were aligned together to correct for
motion, and spatially normalised via co-registration with
the structural scan, and smoothed with a 6 mm Gaussian
kernel. For analysis with the general linear model (GLM) in
SPM, a design matrix was created by convolving the onset
time of the checkerboard blocks with the canonical
haemodynamic response function and its first derivative.
The six parameters from the motion correction were also
included in the design matrix. A high pass filter of 128 s
was used, and serial correlations were removed with SPM’s
AR(1) model. For analysis of the LGN, the ‘thalamus-
visual’ region of interest (ROI) in the SPM anatomy toolbox
[21], which overlies the LGN, was used, with blood oxygen
level dependent (BOLD) activity averaged across both
hemispheres. For each participant, the magnitude of fMRI
activation in the LGN ROI was determined by averaging the
relevant beta parameter from the GLM.
Post mortem tissue samples
All brain tissue was obtained from Newcastle Brain Tissue
Resource (NBTR), a UK Human Tissue Authority–
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approved research tissue depository, and ethical approval
was granted by Newcastle University ethics board and the
Joint Ethics Committee of Newcastle and North Tyneside
Health Authority (ref: 08/H0906/136). All subjects had
been part of local prospective clinical studies and had
received detailed clinical assessments during life (JPT, JO’B,
AJT and IGM) and case note review after death. All cases
and controls had consented to the use of their brain tissue
for research purposes. Neuropathological assessment was
conducted by a neuropathologist (JA) according to stand-
ardized neuropathological diagnostic procedures [1,22–
26]. Clinical and pathological data were collated to
establish a consensus clinico-pathological diagnosis.
Three groups of cases were included in the present
study: DLB cases that had experienced complex visual hal-
lucinations during life, AD cases that had not experienced
visual hallucinations during life and aged-control
cases that showed none, or only low, age-associated
neurodegenerative pathology and had no clinical history of
visual hallucinations during life. AD cases were included as
disease controls with severe neurodegenerative pathology
but without visual hallucinations. Cases with severe ocular
pathology, such as glaucoma, were also excluded due to
evidence suggesting that the LGN undergoes degeneration
in these disorders [27]. Cases that had profound visual
impairments were also excluded. Within the criteria speci-
fied, cases were selected based upon the availability of com-
plete LGN tissue. The cohort used for neuropathological
and morphometric analysis in this study consisted of six
DLB cases, seven AD cases and seven controls (Table 1).
Neuropathology sample preparation
At autopsy, the right hemisphere was fixed in 10% forma-
lin, and brain weight and post mortem delay were noted.
Following fixation, the hemisphere was cut into 7 mm
coronal slices, prior to further dissection into blocks for
neuropathological assessment. From these blocks, the
LGN was identified by its distinctive architecture
(Figure 1a) and its location on the ventrolateral surface of
the posterior thalamus.
Staining of tissues
For stereological analysis, 30 μm sections were sampled at
1 mm intervals from the entire LGN and stained with
cresyl fast violet. For immunohistochemical procedures,
10 μm sections were sampled at 1.5 mm intervals from
the entire LGN. Sections were incubated in the primary
antiserum (5G4 anti-α-synuclein, Analytik Jena, Jena,







NFT stage CERAD Drug treatment
1 84 56 DLB 3 Moderate Rivastigmine
2 89 88 DLB 3 Sparse No
3 71 8 DLB 2 Sparse Donepezil
4 71 68 DLB 3 Sparse Donepezil
5 78 83 DLB 1 None Sinemet
6 78 96 DLB 3 Sparse Donepezil
7 78 23 Control 2 Sparse No
8 74 45 Control 2 Frequent No
9 85 95 Control 2 None No
10 77 83 Control 2 None No
11 73 25 Control 0 None No
12 80 16 Control 2 None No
13 85 57 Control 2 None No
14 76 6 AD 6 Frequent Rivastigmine
15 91 22 AD 5 Frequent Donepezil
16 85 32 AD 5 Frequent Donepezil
17 77 63 AD 6 Frequent No
18 81 73 AD 5 Frequent No
19 93 34 AD 5 Moderate Donepezil
20 86 51 AD 6 Frequent No
Braak NFT stage, neurofibrillary pathology stage as outlined in Braak et al.’s study [26]; CERAD, consortium to establish a registry of AD as
outlined in Gearing et al.’s study [24]; PM delay, interval from time of death to autopsy.
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Germany, 1:4500; 4G8 anti-amyloid-β peptide, Covance,
Princeton, NJ, USA, 1:15 000; AT8 anti-phosphorylated
tau, Autogen, Holliston, MA, USA, 1:4000; anti-GAD65/
67, Sigma Aldrich, St. Louis, MO, USA, 1:12 000; anti-
parvalbumin, Sigma Aldrich, 1:8000; anti-calretinin,
Sigma Aldrich, 1:1000; anti-calbindin, Sigma Aldrich,
1:500; anti-calbindin, Merck Millipore, Darmstadt,
Germany, 1:100). Visualization of antibody binding uti-
lized the Menarini X-Cell-Plus HRP Detection Kit
(Menarini, Berkshire, UK).
Stereological analysis
Stereological analysis employed the use of a Zeiss
AxioVision Z.1 microscope equipped with a motorised
stage (Zeiss, Oberkochen, Germany), coupled to a com-
puter with Stereologer software (Bethesda, MA, USA).
Measures were taken of both the magnocellular and
parvocellular cell populations of the LGN. Magnocellular
and parvocellular cells were characterized on the basis of
location and morphology (Figure 1b [28]). The laminar
structure of the LGN is divided based on cellular popula-
tions, with two magnocellular ventral layers (layers 1
and 2) and four parvocellular dorsal layers (layers 3–6).
As noted previously [29], ‘islands’ of magnocellular neu-
rones exist outside of the two ventral layers of the
LGN that are easily distinguished based on morphology
and staining intensity with cresyl fast violet [28]. These
were also included in the counts of magnocellular
neurones.
To determine the number of cells in the LGN, volume
was assessed using Cavalieri’s principle, and cell density
measures were assessed using the optical disector (as
described in Mouton et al. [30] (see Appendix S1).
Figure 1. The structure of the LGN. (a) Shows a typical LGN approximately in the middle coronal level, with clear lamination. (b) Shows how
the LGN was divided into magnocellular (black) and parvocellular (grey). (c) Shows typical LGN cells with a point grid, and (d) shows disector
frames used to perform neuronal and glial cell counts within the LGN. Scale bars: (a) and (b) = 1 mm, (c) = 200 μm and (d) = 10 μm.
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Disector frames were placed in a uniform, random
arrangement (Figure 1c) to calculate the density of cells
within a defined region (Figure 1d).
For the present study, only points that fell within
the layers being investigated (i.e. magnocellular or
parvocellular) were sampled for analysis (Figure 1b). In
anterior and posterior regions, the delineation of cell
populations is complicated by the absence of corporeal
lamination of the LGN. Therefore, a division was made to
include cells most resembling magnocellular neurones
with magnocellular analyses and those most resembling
parvocellular neurones with parvocellular analyses [28].
Magnocellular and parvocellular section thickness
did not significantly vary across disease groups
(magnocellular F = 1.099, P = 0.356; parvocellular
F = 1.154, P = 0.339). The mean coefficient of error (CE)
for neuronal and glial cell estimates was calculated using
the Gundersen–Jensen method [31] (see Appendix S1).
CE values showed a high degree of precision, with
magnocellular neurone counts having a mean CE value of
0.0663 and magnocellular glial cell counts having a mean
CE value of 0.0391. Parvocellular neurone counts had a
mean CE value of 0.0699 and parvocellular glial cell
counts had a mean CE value of 0.0449.
Quantification of neuropathological lesions
Images of the entire LGN were captured in sampled sec-
tions using a Nikon 90i microscope with a 20 × magnify-
ing objective and DsFi1 camera (Nikon, Tokyo, Japan)
coupled to a PC. These images were imported into the NIS
elements software, and thresholds were determined sepa-
rately for AT8, 4G8 and 5G4 immunoreactivity (as
described by Mandler et al. [32]). This allowed analysis of
immunopositive signals, without detection of nonspecific
background staining or physiological amyloid precursor
protein, as they did not reach the size nor intensity thresh-
old for detection. The area that was immunopositive for
each antibody in the LGN was recorded and a mean gen-
erated across all images taken of the LGN, from all sections
per case. This gave a final result of the mean percentage
area stained per case.
Densitometric analysis of LGN
neuronal populations
Images of the entire LGN were acquired in sampled
sections using a Zeiss Axioplan 2 microscope (Zeiss,
Oberkochen, Germany) with a 20 × magnifying objective
and 3-chip CCD true colour camera (JVC, Yokohama,
Japan) coupled to a PC. These images were analysed using
ImagePro Plus v.4.1 image analysis system (Media Cyber-
netics, Bethesda, MA, USA). Based on the techniques
described in Perry et al.’s study [33], the mean percentage
area stained on sections was determined. Each case,
therefore, had a mean value generated across all sections
analysed.
Despite a previous study [20] suggesting that calbindin
labels koniocellular neurones, no immunoreactivity was
observed in the LGN with various titrations of calbindin
antibodies.
Statistical methods
Demographic group comparisons from the neuroimaging
cohorts were conducted using parametric and categorical
statistics where appropriate. Group comparisons of the
beta parameter magnitude of fMRI activation in the LGN
ROI were carried out using analysis of variance (anova)
with post hoc t-tests.
To assess the differences in neuronal number, glial
number, neuronal volume and densitometric data
between DLB, AD and control cases, an analysis of covari-
ance was conducted, with age at death and post mortem
delay as covariates. Significant main effects were followed
by pairwise comparison of differences, and no Bonferroni
corrections for multiple comparisons were applied due to
the relatively small sample size [28]. These analyses
were two way and with the alpha level set at 0.05.
Densitometric and neuropathological data were analysed
using anova and Kruskal–Wallis tests (as appropriate)
and correlated using Spearman’s rho.
Results
Demographic variables
In the neuroimaging cohort, patients and controls were
matched similarly for age, visual acuity and gender
(Table 2). As expected, patients had greater cognitive
impairment than controls, although AD and DLB were
similarly matched for global measures (Mini Mental State
Examination and Cambridge Cognitive Examination
total). DLB patients had more parkinsonism, fluctuations
and hallucinations but were less impaired in the memory
domain compared with AD cases.
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For the post mortem cohort, no significant differences in
post mortem delay (P = 0.253) or age (P = 0.415) were
found between groups.
Neuroimaging results
On ROI analysis, significant BOLD activity was noted in
the LGN (Figure 2) in DLB (0.24 ± 0.24; t = 4.22,
P = 0.001) and controls (Beta estimate 0.16 ± 0.21;
t = 3.18, P = 0.005) but failed to reach significance
in AD (0.16 ± 0.35; t = 1.82, P = 0.09). However, there
were no differences in activity between groups for the
checkerboard stimulus in LGN (F = 0.54; P = 0.59). There
were also no significant correlations between BOLD acti-
vation in the LGN and any of the clinical variables includ-
ing neuropsychiatric inventory hallucinations subscale, a
clinical marker for the severity and frequency of visual
hallucinations.
Stereological analyses
Results from stereological analyses are summarised in
Table 3.
There was a significant main effect of diagnosis on
parvocellular neurone number (F = 5.845, P = 0.013)
with post hoc pairwise comparisons showing a significant
21.6% decrease in AD compared with DLB (P = 0.004)
and a trend towards a significant 15.8% reduction in AD
compared with controls (P = 0.064). Glial cell number dif-
fered across diagnostic groups (F = 4.118, P = 0.038) in
parvocellular layers, with a significant 26.8% decrease in
AD compared with DLB cases (P = 0.012). Magnocellular
neurone and glial cell number was not significantly differ-
ent across diagnostic groups.
Table 2. Demographic, cognitive and motor characteristics of participants included in neuroimaging study
Control (n = 19) AD (n = 15) DLB (n = 17) ANOVA P-value
Age (years) 77.6 (7.1) 82.5 (9.2) 81.5 (5.5) 0.12
Gender (males : females) 11:8 9:6 9:8 1.00
UPDRS motor subscale 0.9 (1.6) 2.8 (3.0) 33.5 (14.4) <0.001*,†
MMSE 29.0 (1.2) 20.8 (4.4) 19.0 (5.1) <0.001*,‡
CAMCOG total score 96.5 (3.4) 66.5 (14.4) 64.5 (14.4) <0.001*,‡
CAMCOG executive subscore 22.1 (3.4) 12.7 (5.2) 10.5 (4.9) <0.001*,‡
CAMCOG memory subscore 23.6 (2.1) 10.3 (5.1) 15.4 (4.3) <0.001*,†,‡
Visual acuity (decimalised) 0.64 (0.29) 0.68 (0.22) 0.58 (0.22) 0.62
CAF – 3.0 (4.6) 7.9 (4.5) <0.001§
NPIhall – 0.4 (0.9) 2.9 (2.3) 0.006§
On cholinesterase inhibitor – 14 (93.3) 13 (76.5) N/A
On antiparkinson medication – – – N/A
L-dopa dose equivalent (mg)§ – – 145.8 (72.1) N/A
*Controls vs. DLB P ≤ 0.001; †AD vs. DLB P ≤ 0.001; ‡Controls vs. AD P ≤ 0.001; §AD vs. DLB comparison only. DLB, dementia with Lewy bodies;
UPDRS, Unified Parkinson’s Disease Rating Scale; MMSE, Mini-Mental State Examination; CAMCOG, Cambridge Cognitive Examination; CAF,
Clinician Assessment of Fluctuation; NPIhall, Neuropsychiatric Inventory hallucinations subscale score (frequency × severity of hallucinations).
Figure 2. fMRI image of activation in response to checkerboard
stimulus in the whole group, overlaid on an age-matched average
structural scan. Crosshair is centred on the right LGN. Yellow-red
colour scale shows the t statistic, thresholded at P < 0.001
(uncorrected for multiple comparisons).
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In parvocellular layers, no significant difference in the
ratio between glial cells and neurones across groups was
observed. However, in magnocellular layers, a significant
main effect of glial: neuronal cell number ratio across
groups (F = 7.733, P = 0.005) was found, with a signifi-
cant 38% increase noted in AD compared with control
(P = 0.001) and a significant 23.3% increase in AD com-
pared with DLB (P = 0.041).
Across all cases and controls, Braak stage was nega-
tively correlated with the number of parvocellular neu-
rones (rho = −0.473, P = 0.035) and the number of
magnocellular neurones (rho = −0.444, P = 0.05).
The results of the stereological analysis showed high
levels of variation in cell number between cases (Table 3).
However, neither the duration of cognitive decline nor the
age at onset of clinical symptoms was significantly corre-
lated with magnocellular or parvocellular neuronal or glial
cell number.
Neuropathology
All cases exhibited an absence of both Lewy body and tau
pathology within the LGN, apart from occasional sparse
AT8-immunoreactive threads in Braak stage 6 AD cases.
4G8 immunoreactivity, as an indicator of amyloid-β
pathology, was present in all cases in varying degrees and
was primarily situated in the parvocellular layers of the
LGN.anova suggested a significant main effect of diagnosis
upon percentage area stained for amyloid-β (F = 7.336,
P = 0.005), with a significant 790% increase in amyloid-β
density observed in AD (Figure 3) when compared with
controls (P = 0.004), whereas no respective significant dif-
ference was seen between DLB and control, and a trend
towards a significant difference was seen between AD and
DLB (P = 0.055; Figure 3). Across all cases and controls,
amyloid-β was significantly positively correlated with
Braak stage (rho = 0.574, P = 0.007).
Densitometric analysis of GABAergic
interneurones and neuronal populations
in the LGN
GAD65/67 was used to identify GABAergic neurones
present within the LGN.The percentage area of GAD65/67
immunoreactivity (Figure 3) did not differ significantly
between DLB (0.43 ± 0.008), control (0.43 ± 0.009)
and AD (0.23 ± 0.009; Figure 3). However, GAD65/67
percentage area was significantly correlated with
parvalbumin immunoreactivity (rho = 0.58, P = 0.006),
suggesting that interneurone populations increase linearly
with the projection neurone populations.
Calcium-binding proteins were used to identify neuronal
subpopulations present within the LGN [20]. Parvalbumin
percentage area immunoreactivity (see Figure 3) did not
significantly differ between DLB (16.28 ± 1.4), control
(15.99 ± 1.2) and AD (12.98 ± 1.3). Calretinin percent-
age area stained (see Figure 3) also did not significantly
differ between DLB (2.69 ± 0.23), control (2.79 ± 0.2) and
AD (2.33 ± 0.22). However, parvalbumin percentage area
Table 3. Stereological data showing magnocellular (MG) and parvocellular (PV) neuronal and glial cell counts in the LGN
Control DLB AD
MG neuron number 161 × 103 ± 12 954 155 × 103 ± 13 992 132 × 103 ± 12 954
MG glia number 821 × 103 ± 79 053 879 × 103 ± 85 387 928 × 103 ± 79 053
MG neuron: glial cell ratio 5.13 ± 0.319 5.74 ± 0.345 7.08 ± 0.319*
PV neuron number 131 × 104 ± 89 641 141 × 104 ± 96 823 111 × 104 ± 89 641*
PV glia number 475 × 104 ± 463 999 578 × 104 ± 501 177 423 × 104 ± 463 999
PV neuron: glial cell ratio 3.66 ± 0.26 4.01 ± 0.28 3.89 ± 0.26
*P < 0.05.
Figure 3. Bar chart showing percentage area stained by antibodies
in the LGN across groups (*P = 0.005).
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was negatively correlated with Braak stage (rho = −0.562,
P = 0.008) in all cases and controls.
Discussion
The present study revealed similar levels of BOLD activity
in the LGN ROI across groups, although in AD a significant
BOLD response could not be detected. Stereological analy-
sis showed no changes in the number of neurones in the
LGN between aged-control and DLB cases using post
mortem tissue. However, in AD, the severity of gliosis in the
magnocellular layers was significantly higher than in DLB
and controls. These changes were accompanied by a mod-
erate loss of parvocellular neurones in AD compared with
DLB cases, and increased amyloid-β pathology was found
in AD cases.
There is a paucity of work describing how the LGN is
affected in degenerative dementia disorders, particularly
DLB. However, the visual symptomatology of DLB, which
includes hallucinations and delusional misidentification
[1], suggests that there may be pathological changes in
the visual system that influence these phenomena.
Despite previous findings showing occipital changes in
DLB cases using functional neuroimaging, the present
study revealed no significant difference between DLB and
control cases in the LGN. This suggests that physiological
changes to the visual system that may promote hallucina-
tions in DLB do not occur through alterations to the LGN. A
weakness of the present study is that the fMRI was done on
a different set of subjects to the post mortem sample, which
precluded direct comparison of alterations in fMRI activity
with findings from stereological and pathological analyses.
In addition, the resolution of the fMRI is large compared
with the size of the LGN, and a standard ROI was used to
determine LGN activity. Thus, it may be that in the AD
group, greater global atrophy could have resulted in less
accurate placement of the ROI, which may explain the
difficulty in detecting a significant signal in the AD group.
However, this is unlikely to have affected the finding of no
significant difference in activity between the control and
DLB groups.
As previously reported [18], an increase in amyloid-β
pathology was found in the LGN in AD cases. However, the
general absence of tau pathology in the LGN, contrasted
with a previous report [17], but was consistent with
another [18]. The absence of Lewy body pathology was
also consistent with previous work [19]. Although the
amyloid-β burden was high in some DLB cases, it was
typically indistinguishable from control cases, and no
overall significant difference was observed between DLB
and control cases. Braak stage was also found to be posi-
tively correlated with the amount of amyloid-β in the
LGN and negatively correlated with the number of
magnocellular and parvocellular neurones and the per-
centage area of parvalbumin immunoreactivity. This sug-
gests that the degree of degeneration in the LGN may be
related to global neurofibrillary pathology burden.
Although previous work on the visual system in DLB
has revealed retinal abnormalities [8,10–12], the relative
sparing of the LGN in DLB shown in the present study is
unprecedented. It is tempting to speculate that abnormal
retinal input, processed by an intact LGN, may play a role
in the pathophysiology of visual hallucinations in DLB.
Normal processing of abnormal retinal input could lead to
the distribution of fragmented or distorted visual informa-
tion, which requires completion, to visual cortical areas.
In AD, where LGN abnormalities were found, and retinal
abnormalities have been described [11], altered LGN pro-
cessing may act as a gating function and avoiding cortical
processing of altered perceptions.
The finding of specific gliosis in the magnocellular
layers of the LGN in AD suggests potentially inflammatory
conditions in this population of LGN neurones in AD. This
may be related to the finding of specific magnocellular
deficits in AD patients who have undergone physiological
testing with electroretinograms and visual evoked poten-
tials [34].
Neuropathological changes occur to the primary visual
cortex in AD [35], whereas less pathology is typically
observed in DLB [36]. As there is considerable reciprocal
connectivity between the primary visual cortex and LGN
[37], it is possible that the pathological changes observed
in the LGN in AD, but not DLB, result from degeneration of
the primary visual cortex in AD [35]. As pathology occurs
in the primary visual cortex in late stages of AD [23,26],
and the LGN degeneration observed is relatively mild, it is
tempting to speculate that the changes observed in the
LGN are a late feature of AD pathology. However, if the
changes do occur at late stages of AD, it is difficult to say
how much of an influence that these changes may have
upon the clinical phenotype.
As with most human post mortem studies of this nature,
sample size was limited by tissue availability. Moreover, the
strict sampling strategy demanded by stereological proto-
col, where whole, intact structures are required, further
reduced the patient cohort. Shrinkage following formalin
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fixation is well understood [38] and, despite efforts to
conduct this study based on unbiased principles, the
unwitting introduction of bias by the differential rate of
shrinkage across disease groups, while unlikely, cannot be
excluded.
The present study implies that the LGN and, by exten-
sion, the geniculocortical visual pathway are relatively
preserved in DLB but not AD. This preservation of the LGN
suggests that the manifestation of visual hallucinations in
DLB may be due to normal processing of altered visual
input, upstream pathology in the visual system and/or
pathological changes to brain structures elsewhere that
have yet to be identified.
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